CancerDrs

Lung Cancer clinical trials in Idaho

8 actively recruiting lung cancer trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
Phase 2, Phase 3 Recruiting Network

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Idaho:
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
  • Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
Phase 3 Recruiting Industry

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Idaho:
  • Saint Alphonsus Regional Medical Center - Boise — Boise, Idaho
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Luke's Cancer Institute - Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Walter Knox Memorial Hospital — Emmett, Idaho
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Idaho:
  • Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
  • Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
  • Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
  • Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
  • Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Recruiting Industry

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at disconti…

Sponsor: N-Power Medicine
NCT ID: NCT07028489
Sites in Idaho:
  • Kootenai Clinic Cancer Services Coeur d'Alene — Coeur d'Alene, Idaho

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27